IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
73.86
+0.53 (+0.72%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close73.33
Open73.80
Bid68.18 x 1400
Ask0.00 x 800
Day's Range72.47 - 74.43
52 Week Range39.07 - 86.58
Volume995,437
Avg. Volume1,130,080
Market Cap10.222B
Beta (3Y Monthly)1.95
PE Ratio (TTM)35.68
EPS (TTM)2.07
Earnings DateMay 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est69.21
Trade prices are not sourced from all markets
  • Biogen Looks to 23 Clinical Programs for Growth
    Motley Fool17 hours ago

    Biogen Looks to 23 Clinical Programs for Growth

    First-quarter sales were up 11%, but future growth is less certain.

  • PR Newswireyesterday

    Ionis Pharmaceuticals to hold first quarter 2019 financial results webcast

    CARLSBAD, Calif., April 25, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that it will host a live webcast on Thursday, May 9th at 11:30 a.m. Eastern Time to discuss its first quarter 2019 financial results and report on pipeline and business progress. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.

  • Zacks2 days ago

    Solid Earnings Boost S&P, NASDAQ to New Closing Highs

    Solid Earnings Boost S&P;, NASDAQ to New Closing Highs

  • GlobeNewswire2 days ago

    Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Wednesday, May 8th at 4:30 p.m. Eastern Time to discuss its first quarter 2019 financial results and report on pipeline and business progress. Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. (IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. All six drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology.

  • Is Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.3 days ago

    Is Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Balance Sheet Strong Enough To Weather A Storm?

    Investors pursuing a solid, dependable stock investment can often be led to Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a large-cap worth US$10b. One reason being its ‘too big to fail’ aura which gives it the appearance of a strong...

  • The Zacks Analyst Blog Highlights: Alteryx, CommScope, Ionis Pharmaceuticals and Apache
    Zacks4 days ago

    The Zacks Analyst Blog Highlights: Alteryx, CommScope, Ionis Pharmaceuticals and Apache

    The Zacks Analyst Blog Highlights: Alteryx, CommScope, Ionis Pharmaceuticals and Apache

  • Hedge Funds Dropped The Ball On Ionis Pharmaceuticals, Inc. (IONS)?
    Insider Monkey7 days ago

    Hedge Funds Dropped The Ball On Ionis Pharmaceuticals, Inc. (IONS)?

    Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]

  • 4 Large-Cap Stocks Worth Looking Into Right Now
    Zacks8 days ago

    4 Large-Cap Stocks Worth Looking Into Right Now

    Here are 4 large-cap stocks from varied industries that may be worth your money.

  • Why A Highly Rated Biotech With A 54% Gain This Year Is Being Gutted
    Investor's Business Daily9 days ago

    Why A Highly Rated Biotech With A 54% Gain This Year Is Being Gutted

    Ionis Pharmaceuticals was slammed Wednesday on competitive gene-therapy data from Novartis' AveXis unit and amid apparently disappointing comments from Roche in Huntington's disease.

  • Here's Why Ionis Pharmaceuticals Slumped Today
    Motley Fool9 days ago

    Here's Why Ionis Pharmaceuticals Slumped Today

    Information from competitors and a collaborator sent the high-flying biotech lower.

  • Zacks9 days ago

    NASDAQ Back Above 8,000

    NASDAQ Back Above 8,000

  • 5 Stocks to Sell as They Climb to New Highs
    InvestorPlace15 days ago

    5 Stocks to Sell as They Climb to New Highs

    More than ten years have now passed since the market saw its post-crisis low. The S&P 500 index has risen by almost 375% in that period. Many equities have risen by much more -- in some circumstances making them stocks to sell.This has worried technical strategists such as Bob Farrell, who see new market highs as a sign of worry. Mr. Farrell believes that "fear of missing out" could lead to the next market top. After hitting that high point, he predicts wide market swings and below-market returns over the next decade.Stocks such as Amazon (NASDAQ:AMZN) or Netflix (NASDAQ:NFLX) have supported high multiples for several years. However, history shows that stocks tend to eventually reach "fair value." A decline like Mr. Farrell predicts would likely bring high-flying equities closer to fair value.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFor now, many stocks to watch trade near 52-week highs. In light of a coming market decline, these five stocks to sell could see a significant drop in their prices: Etsy (ETSY)Source: Meaghan O'Malley via Flickr (Modified)Amid intense competition, Etsy (NASDAQ:ETSY) has stood out among e-commerce sites. It has become a hub by which artisans can market handmade, vintage and unique items. With its website, Etsy brings these products to a worldwide audience. It also serves as a home for a market that would not fit well on an Amazon or an eBay (NASDAQ:EBAY).This niche has helped propel ETSY stock to near record highs in recent days. Analysts forecast 16.4% profit growth for the year. Although they predict a 50.7% profit increase next year, they expect average earnings growth in the teens for the foreseeable future.This will hold Etsy in good stead. Still, it may not support the current valuation of ETSY stock long term. The most recent earnings beat sent ETSY higher by more than 16%. This spike propelled the equity to a record high. Although the stock fell slightly following that move, it still supports a forward P/E ratio to over 62. It also leaves the equity with a trailing PE of just over 100.Further, factors such as the 13-plus price-to-sales ratio help to make Etsy one of the stocks to sell. I expect ETSY stock will become a long-term winner. However, at current multiples, investors should stay on the sidelines. Ionis Pharmaceuticals (IONS)Source: Shutterstock Biotech company Ionis (NASDAQ:IONS) treats diseases through the manipulation of genes. This antisense technology, along with its work in RNA therapies, has helped it to develop a pipeline of more than 40 drugs. Medicines such as Spinraza, developed with Biogen (NASDAQ:BIIB), and the newly-approved Tegsedi have helped to bolster the company's bottom line.However, despite successes with Spinraza and other drugs, the state of IONS stock could cause concern. Ionis beat earnings estimates in its last earnings report. It also reported 14.5% revenue growth and guided 2019 revenues higher by $725 million. However, one might question whether that justifies its forward P/E to about 127.Profit growth could also cause concerns. Investors expect earnings to increase by an average of 40% per year over the next five years. However, that estimate may prove high over time as earnings estimates continue to fall. As recently as 90 days ago, Wall Street had predicted 2019 earnings of 39 cents per share. That estimate today stands at 17 cents. Profit estimates for 2020 have also come down during that time.IONS stock should still perform well in the long term. However, IONS needs time to catch up to its valuation. Given this multiple, I would place it on the stocks to sell list for now and wait to buy at a more reasonable valuation. Pegasystems (PEGA)Source: Shutterstock Though it has existed since 1983, many investors remain unfamiliar with Pegasystems (NASDAQ:PEGA). Those who have heard of PEGA know it best as a CRM company who produces the Pega Platform. This could-based solution helps sales and marketing professionals. It brings customer service solutions and digital process automation to numerous industries. It also helps Pegasystems earn revenue through software licensing, maintenance fees, and consulting services.Despite a long history, it has seen most of its stock price growth occur over the last decade. Trading as a penny stock as late as 2008, it has now climbed to new highs in the $67 per share range.However, like many cloud equities, PEGA stock trades at a premium that likely places it on the stocks to sell list. PEGA's forward P/E ratio has risen to just above 85. Wall Street forecasts profits growth averaging 20.6% per year over the next five years. That growth rate should command a higher-than-average multiple.Still, its current P/E ratio indicates that the stock price has moved ahead of company earnings. As a $5.2 billion cloud company, with double-digit profit growth, PEGA stock could easily grow from these levels long term. However, at over 85 times earnings, it appears more likely to correct in the near term. SBA Communications (SBA)Source: iStockphoto SBA (NASDAQ:SBAC) owns and operates infrastructure for wireless communications across both North and South America. It earns revenue through both site development and leasing. Moreover, with the development of 5G in recent years, SBA's role has become more crucial.Two years ago, SBAC stock completed the process to become a real estate investment trust (REIT). However, thanks to capital loss carryovers from previous years, SBAC will not offer the usual dividend benefits of a REIT until at least next year. Despite the lack of a payout, the stock trades at a forward P/E of about 104. This comes in much higher than both American Tower (NYSE:AMT) and Crown Castle (NYSE:CCI) who currently pay dividends.Unlike its pre-REIT days, Wall Street predicts profits and profit growth for SBAC stock. In fact, they estimate that earnings will increase by an average of 85.3% per year over the next five years.So why is it one of the stocks to sell?Ordinarily, I could tolerate a 100-plus P/E with that kind of earnings growth. However, analysts continue to revise earnings for the company downward. Also, even when SBAC stock finally begins to pay dividends, profit levels indicate yields will come in well below the current 3.72% average yield for equity REITs.Given the importance of 5G and the new REIT structure, I expect SBAC stock to perform well long term. However, when AMT and CCI offer dividends at a lower multiple, SBA looks like a sell. Twilio (TWLO)Source: Web Summit Via FlickrFew of the stocks to sell have seen a faster rise than Twilio (NYSE:TWLO). Twilio pioneered the Platform-as-a-Service (PaaS) cloud niche. Their technology powers mobile apps, allowing companies such as Lyft (NASDAQ:LYFT) and Grubhub (NYSE:GRUB) to perform their basic functions.As the dominant company in this niche, it has posted remarkable growth numbers. Analysts forecast revenue growth of 65.6% this year and 32.2% in 2020. Over the next five years, they also believe average annual profit growth to come in at 36.5%. Even as companies such as RingCentral (NYSE:RNG) and Zendesk (NYSE:ZEN) seek to compete in this space, Twilio should continue to maintain its rapid growth rate for the foreseeable future.However, even the best companies justify only so much value. Since late 2017, TWLO stock has risen by more than fivefold. As a result, it is supporting a forward P/E ratio of over 450! Admittedly, if investors remained optimistic, and TWLO consistently met or beat estimates, I would not foresee a crash. However, the bull market has reached its 11th year. If investors turn on the market, TWLO stock will have no grounds for its current price.I expect Twilio to become one of the more critical companies in the tech industry. However, with its current multiple and the potential negative catalyst, investors should avoid TWLO stock at these levels.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Best Dividend Stocks to Buy for Every Investor * 7 Catalysts That Will Send Marijuana Stocks Soaring in 2019 * 8 Risky Stocks to Watch as Earnings Season Kicks Off Compare Brokers The post 5 Stocks to Sell as They Climb to New Highs appeared first on InvestorPlace.

  • Zacks16 days ago

    S&P Streak Ends as Stocks Step Back

    S&P; Streak Ends as Stocks Step Back

  • Markit17 days ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Ionis Pharmaceuticals Inc NASDAQ/NGS:IONSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding IONS is favorable, with net inflows of $113.41 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • PR Newswire18 days ago

    Ionis Pharmaceuticals to Provide Corporate Update at 2019 Annual Meeting of Stockholders

    CARLSBAD, Calif., April 8, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) today announced that management will present a general corporate update in conjunction with its 2019 Annual Meeting of Stockholders and Open House on Thursday, June 6 at 2:10 p.m. Pacific Time (5:10 p.m. Eastern Time) in Carlsbad, CA.

  • 3 Stocks That Have Doubled and Still Have Room to Grow
    Motley Fool18 days ago

    3 Stocks That Have Doubled and Still Have Room to Grow

    Sometimes the best future returns come from companies that have already shown themselves to be successful.

  • 7 A-Rated Healthcare Stocks for Industry Expansion
    InvestorPlace22 days ago

    7 A-Rated Healthcare Stocks for Industry Expansion

    According to the Centers for Medicare and Medicaid Services, healthcare spending in 2017 represented nearly 18% of U.S. GDP that year. And it projected that spending will rise 5.5% annually through 2026, when that spending will represent 20% of the country's GDP -- a boon for healthcare stocks.To put this in perspective, the U.S. defense budget is about 18% of the entire U.S. budget and we outspend every other nation on this planet in defense spending by a significant margin.The U.S. healthcare system is being debated again and may well be a significant issue in the upcoming presidential election.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut the reality is, the U.S. population is getting older and that means more chronic diseases begin to take their toll. Also, older people tend to take up a larger portion of healthcare costs as their health begins to fail. * 7 Biometric Stocks to Watch as AI Rises That means there will be an unstoppable growth trend in place for healthcare companies. The A-rated healthcare stocks I feature here are well placed to take advantage of this trend. And they're small enough that their growth will outpace their larger competitors and may make them interesting takeover targets. Healthcare Stocks: Masimo (MASI)Source: FlickrMasimo Corp (NASDAQ:MASI) is the perfect example of how technology is transforming healthcare.Once, heading the doctors or the hospital was a regular occurrence for patients with chronic issues like heart disease or diabetes. But now, monitoring technologies, where patients can wear a device that essentially tracks their functions and the data can either be downloaded remotely or by the patient and sent to the doctor, are becoming increasingly common.And MASI is one of the leaders in the field. It is also one of the two top players in the pulse oximetry sector. These are devices that check the oxygen saturation level a person's blood. Hospitals use these a great deal and generally the contracts run on a five-year basis, so income is steady and once they're in place it's unlikely the hospitals will switch over to a new type of unit, so there are solid competitive moats.MASI is up almost 59% in the past 12 months, and half of that has come in 2019. This is the kind of company that can grow with the market regardless of what U.S. healthcare ends up looking like. Ionis Pharmaceuticals (IONS)Source: Shutterstock Ionis Pharmaceuticals (NASDAQ:IONS) was founded by leading biotech scientists to expand the use of antisense therapy. It's a new form of treatment that is at the cutting edge of science medicine.Basically, if you can find a genetic marker for a disease, you can synthesize a strand of RNA that can render that gene inactive, so it doesn't reproduce. The potential uses extend to cancers, heart disease, diabetes, asthma, arthritis … the list goes on.This technology has the potential to help both rare and common maladies, many of which don't have current effective treatments. * The Elite 8 Stocks to Buy for Massive Outperformance IONS is already partnered with a number of larger pharmaceutical firms and is up 94% in the past year, with plenty of headroom left. Osiris Therapeutics (OSIR)Source: Shutterstock Osiris Therapeutics (NASDAQ:OSIR) has a market cap around $650 million, so it's in that perfect spot where it has the potential for big growth on its own, or it could be a target for takeover at a nice premium for a larger pharma looking for a unique product line.OSIR specializes in regenerative medicine products. What that means is, it uses stem cells to build medicines that help everything from wound healing to bone marrow graft acceptance. It's a unique space that has significant possibilities now and for the future.It currently has five products on the market that are focused on wound healing, ligament repairs and surgical wraps on tissues. All promote better healing outcomes with less infections than traditional methods.Last quarter it sold the rights to one of its top stem cell drug for $100 million, so it's work is being recognized. OSIR stock is up 118% for the year and 46% in 2019. Ensign Group (ENSG)Source: Shutterstock Ensign Group (NASDAQ:ENSG) specializes in post-acute care staffing for a wide variety of facilities that would need these services. Some of the most obvious would be assisted living facilities, home health care, rehab facilities and hospice. It manages 250 companies in more than 12 states, around the U.S.This is precisely the sort of sector that will be in huge demand in coming years. While all the technology and new drugs are great, there will still need to be qualified people helping support the patients as they recover and attempt to maintain active lifestyles.It continues to expand its base in California, where the company is headquartered, having just bought another company in Southern California. But its operations beyond the state show that it has what it takes to expand its model where the most opportunity is. * 10 Tech Stocks That Transformed Their Business Up 94% in the past year, its size makes it a potential takeover target or a big grower on its own. Genomic Health (GHDX)Source: Shutterstock Genomic Health (NASDAQ:GHDX) specializes in genomic diagnostic testing, specifically for cancer. The testing allows for patients and doctors to create individualized treatment strategies for patients.This is important because it means patients get the treatment they need -- they're not over-treated or under-treated. And that is good for the whole healthcare system as well as the patients.Again, this kind of diagnostic tool will be something that insurers, hospitals and patients can get behind since it allows care to better suited to each patient with the goal of lowering costs and improving outcomes.The stock is up over 112% in the past year and it's still going strong. National Research Corp (NRC)Source: Shutterstock National Research (NASDAQ:NRC) is all about delivering all the best possible outcomes for patients with their healthcare providers. NRC sees the current and future healthcare sector as patient-driven, and that is not the traditional model.The patient wasn't much more than a bundle of symptoms that were inserted into the healthcare machines to get repaired and sent back out into the world before. Now, it's about creating an experience that not only serves the patient better, but is able to deliver better outcomes and fewer return visits. It's looking at numbers that view the system more holistically.And NRC provides those numbers from its research.While it has been around since 1981, NRC is just coming into its own. And it would be a great takeover target for one of the big healthcare insurers or a large hospital chain. * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos Up 30% in the past year, NRC also delivers a near-2% dividend. AngioDynamics (ANGO)Source: Flickr>AngioDynamics (NASDAQ:ANGO) is a medical device company that specializes in equipment that's used for vascular access, surgery, vascular disease and oncology. It actually made a new acquisition earlier this year to increase its oncology suite of products.Specialty medical device makers are in particular demand globally, since the good ones tend to get most of the business. Medicine is a very conservative practice and tested and true is much more preferable to new and interesting.And generally that's the view from hospitals, insurers and patients. It takes years to put new equipment in place and generally the new equipment is from a trusted equipment maker and not the kid on the block. Having been around since 1988, ANGO fits that bill.Up almost 20% in the past year, the future is bright. And its global potential is huge, as China looks to upgrade its entire healthcare system.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Low-Priced Tech Stocks With Great Potential * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * The Era of Car Ownership Is Over. And These 4 Charts Prove It Compare Brokers The post 7 A-Rated Healthcare Stocks for Industry Expansion appeared first on InvestorPlace.

  • 1 Biotech That Biogen Should Buy ... but Probably Won't
    Motley Fool22 days ago

    1 Biotech That Biogen Should Buy ... but Probably Won't

    The drugmaker has $4.9 billion in the bank.

  • Achillion Meets Enrollment Target in Kidney Disease Studies
    Zacks22 days ago

    Achillion Meets Enrollment Target in Kidney Disease Studies

    Achillion (ACHN) achieves enrollment target in two mid-stage studies evaluating its lead candidate, ACH-4471 in C3G, a devastating disease affecting the kidney.

  • Achillion Completes Enrollment in Rare Blood Disorder Study
    Zacks29 days ago

    Achillion Completes Enrollment in Rare Blood Disorder Study

    Achillion (ACHN) achieves enrollment target in a mid-stage study evaluating its lead candidate, ACH-4471, in paroxysmal nocturnal hemoglobinuria, a rare life-threatening disease of the blood.

  • Zackslast month

    S&P Fights Past Growth Concerns to Reclaim 2800

    S&P; Fights Past Growth Concerns to Reclaim 2800

  • PR Newswirelast month

    Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors

    CARLSBAD, Calif., March 25, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia, Ph.D., has been appointed to the company's board of directors. Dr. Monia currently serves as Ionis' chief operating officer and, as was previously announced, will be appointed chief executive officer of the company in January 2020, succeeding current CEO Stanley T. Crooke, M.D., Ph.D., who will become executive chairman of the Ionis board of directors. With the addition of Dr. Monia, the Ionis board now has a total of 11 members.

  • GlobeNewswirelast month

    Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS) today announced that data from the NEURO-TTR open-label extension study and the clinical impact of TEGSEDI on patients living with hereditary transthyretin amyloidosis (hATTR) will be presented at the American College of Cardiology’s 68th Annual Scientific Session (ACC) in New Orleans, March 16-18, 2019.